MabPair Platform
MabPair Platform
Two Completely Different Antibodies. One Therapeutic Product.
Two Completely Different Antibodies. One Therapeutic Product.
Advantages of MabPair
Advantages of MabPair
MabPair combines the therapeutic potential of two distinct antibodies within a single drug product, offering flexibility in antibody selection, IgG isotypes, and relative ratios. Compared with conventional antibody cocktails, this approach offers potential advantages in product development, administration convenience, and cost efficiency, while supporting therapeutic applications across oncology, immunology, and inflammatory diseases.
MabPair combines the therapeutic potential of two distinct antibodies within a single drug product, offering flexibility in antibody selection, IgG isotypes, and relative ratios. Compared with conventional antibody cocktails, this approach offers potential advantages in product development, administration convenience, and cost efficiency, while supporting therapeutic applications across oncology, immunology, and inflammatory diseases.
Engineering Two Antibodies in a Single Cell Line
Engineering Two mAbs in a Single Cell Line
MabPair employs proprietary antibody engineering technology to address the challenges of heavy-chain and light-chain mispairing during co-expression of two distinct antibodies. Through engineered chain-pairing mechanisms, the platform promotes the formation of the intended antibody structures while minimizing unwanted combinations, enabling the production of two full-length monoclonal antibodies from a single host cell line.
MabPair employs proprietary antibody engineering technology to address the challenges of heavy-chain and light-chain mispairing during co-expression of two distinct antibodies. Through engineered chain-pairing mechanisms, the platform promotes the formation of the intended antibody structures while minimizing unwanted combinations, enabling the production of two full-length monoclonal antibodies from a single host cell line.
MabPair Platform — Intellectual Property
MabPair Platform — Intellectual Property
Patents covering Sound Biologics' proprietary MabPair technology have been issued in the United States, China, and Japan, including U.S. Patent No. 11,130,808 B2 ➤ , titled Mixtures of Antibodies.
➤
➤
Back to Our Science
Back to Our Science
